News

CEO Per von Mentzer presented PharmNovo at the BioStock - Connecting Innovation and Capital Life Science Fall Summit 2022. Watch his presentation addressing the large, unmet medical needs in the neuropathic pain market and learn more about our ongoing clinical trial and how we will achieve project milestones as PharmNovo moves forward.

PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical Trial Manager

Read the story about PharmNovo and our drug candidate PN6047 for neurophatic pain and its ongoing phase I studies in Svenska Dagbladet.

PharmNovo appoints CFO and Clinical lead to strengthen the organization.

We are pleased to inform that during the summer, the application to start

We are pleased to announce that we have raised 67 MSEK in a new share issue led by Sciety.